A Strange Kind of Good News
Here’s a sentence you wouldn’t have expected to write about the supplement industry five years ago: the Health and Human Services Secretary is a fan. Not a polite, distant, photo-op kind of fan — an actual, vocal advocate. During an April fireside chat hosted by the Natural Products Association, the FDA’s deputy commissioner for human foods, George Diamantas, said it plainly: “We certainly want to support the industry, and [Secretary Kennedy] is a big proponent of the dietary supplement industry.” That’s not a throwaway line. It’s a signal of where this industry sits inside an administration that has made nutrition policy, somewhat unexpectedly, one of its loudest priorities. And yet, talk to the lawyers and compliance teams actually living through this moment, and the mood is less celebration, more bracing. Because when Washington pays this much attention to an industry that has spent three decades operating with relatively light federal oversight, that attention comes with homework attached.
The Rulebook Hasn't Changed Since 1994. That's About to End.
The supplement industry has been operating under the same basic rulebook — the Dietary Supplement Health and Education Act — since 1994. Three decades is a long time for any regulatory framework to sit untouched, and the FDA itself seems to agree. As the agency’s own 2026 Human Foods Program priority deliverables document put it, “given the rapid growth of the dietary supplement marketplace and the more than 30 years since enactment of [DSHEA],” the agency is now actively pursuing what it calls dietary supplement oversight modernisation. Practically, that means a few concrete things are landing this year, not someday: final guidance on what companies need to prove before launching a genuinely new dietary ingredient, a faster and more predictable 75-day review clock for those filings, and — according to Skadden’s January 2026 analysis for industry clients — a notably more relaxed approach to label disclaimers paired with a more discretionary enforcement posture. Translation: some rules are loosening. Others are tightening. Almost nothing is staying exactly the same.
MAHA, Explained for People Who Sell Vitamins
If you’ve been even mildly online in the past year, you’ve heard “Make America Healthy Again” mentioned constantly, usually without much explanation of what it actually does to a specific industry’s day-to-day compliance reality. For supplement makers, the honest answer is: quite a lot, and not always in the direction you’d expect. On one hand, the movement’s general suspicion of synthetic, heavily processed ingredients has put supplement brands’ formulations under a brighter spotlight than they’ve faced in years — Skadden’s analysis noted that MAHA-driven scrutiny is “prompting companies to reformulate products and remove artificial dyes in anticipation of policy changes and shifting consumer demand,” well ahead of any final rule actually requiring it. On the other hand, the FDA’s own messaging has been explicitly supportive of the industry as a category — less “crack down on supplements” and more “clean up the bad actors so the rest of the industry isn’t tarred by association.” Diamantas was direct about this too, telling the same April audience that the agency wants to find ways to “eliminate some of those bad actors” specifically so the broader, responsible industry can keep thriving.
The Patchwork Problem: When Every State Has Its Own Rules
Here’s the part that’s genuinely keeping compliance teams up at night: while Washington negotiates the big federal picture, individual states are quietly building their own, much more specific rulebooks — and they don’t always agree with each other, or with federal policy. California’s AB 2034, introduced in February 2026, would require manufacturers to prove to state regulators that any ingredient introduced after 1958 without prior FDA premarket review is actually safe — a significant new burden layered directly on top of federal requirements. A separate California measure, if enacted, would require companies selling protein products in the state to test every lot for arsenic, cadmium, lead, and mercury starting January 1, 2028, and publish the results publicly online. Meanwhile, Skadden’s 2026 outlook flagged a separate and fast-growing trend: states imposing age restrictions specifically on supplements marketed for weight loss and muscle building. None of this is coordinated. All of it is binding. And brands selling nationally are increasingly finding that “compliant in 49 states” isn’t the same thing as “compliant,” full stop.
Congress Wants In, Too
As if a rewritten federal rulebook and a fifty-state patchwork weren’t enough, Congress decided 2026 was the year to weigh in directly. On April 29, the House Energy and Commerce Committee’s Health Subcommittee held a legislative hearing titled “Healthier America: Legislative Proposals on the Regulation and Oversight of Food”, working through a slate of bills touching food, supplements, and infant formula oversight all at once. It’s a useful reminder that supplement regulation in 2026 isn’t being written by any single body — it’s emerging simultaneously from FDA guidance documents, state legislatures, and Capitol Hill hearing rooms, all moving at slightly different speeds and sometimes pulling in slightly different directions. For an industry used to a fairly stable, predictable compliance environment, that simultaneous multi-front activity is itself the headline.
And Through It All: People Are Just... Taking More Vitamins
Step back from the regulatory noise for a second, because the underlying consumer story is almost shockingly simple. According to Glanbia Nutrition’s look at 2026 supplement trends, 94% of Americans have used a supplement in the past year, and almost two-thirds take them very often. Among adults aged 18 to 44, 63% are juggling two or three supplements at once, typically taken first thing in the morning as part of an increasingly routine, habitual ritual — less “medicine,” more “morning coffee, but for your cells.” Tablets and capsules still dominate shelf space, but gummies, liquids, powders, and oral strips are steadily eating into that share, because, frankly, they feel less like medicine and more like a normal part of getting through the day. Recent product launches lean heavily toward energy, digestion, heart health, and cognitive or mood support — a fairly accurate mirror of what an overstretched, anxious, screen-fatigued population says it actually wants help with.
What Decision-Makers Should Be Watching
If you’re trying to operate — or invest — in this category through the back half of 2026, a few things genuinely matter more than the rest of the noise. First, the GRAS (Generally Recognised as Safe) rule sitting at the Office of Management and Budget since December 2025 is the single biggest sleeper issue in the whole sector; Holland & Knight’s analysis notes it could eliminate GRAS self-affirmation entirely and require prior FDA notification for new ingredients — a genuinely structural change to how fast new formulations can reach shelves. Second, watch the hemp and cannabinoid space closely: Congress tightened the federal definition of legal hemp in its FY2026 appropriations package, capping total THC at 0.4 milligrams per container, with the new rules taking effect November 12, 2026 — closing what had become known as the Farm Bill loophole, and forcing reformulation across an entire adjacent product category. Third, keep an eye on retailers, not just regulators: national chains are increasingly setting their own quality bars above the federal floor, and brands that can’t meet those private standards risk losing shelf space regardless of what the FDA technically allows.
So, Good Year or Complicated One?
Probably both, honestly — and probably at the same time. The dietary supplement industry in 2026 has something it hasn’t had in a long while: a genuinely sympathetic ear in Washington, a Secretary who talks about the category as a personal priority, and consumer demand that just keeps climbing regardless of what any regulator decides. But it’s also navigating its most significant rulebook rewrite since the Clinton administration, a fifty-state compliance patchwork that shows no sign of converging, and a Congress that’s decided this is finally the year to legislate directly on food and supplement oversight. Constancy Researchers’ honest read is that the companies who come out ahead won’t be the ones betting on regulatory relief alone — they’ll be the ones treating compliance infrastructure itself as a genuine competitive advantage, because in a year this fluid, knowing the rules first is half the battle.
Looking to navigate geopolitical risks and identify new industry opportunities?
Connect with Constancy Researchers for data-driven insights, geopolitical intelligence, and strategic consulting tailored to your business needs.
